Zerrin Kutlu | Pharmacology | Excellence in Research Award

Published on by Cognitive Scientist Awards

Prof. Dr. Zerrin Kutlu | Pharmacology | Excellence in Research Award

Ataturk University | Turkey

Dr. Zerrin Kutlu is a dedicated biochemist at Ataturk University whose work bridges academic research and translational biomedical applications, with expertise shaped through comprehensive education in biochemistry and continuous engagement in laboratory-based investigations. She has developed strong professional experience in studying oxidative and endoplasmic reticulum stress, inflammation, metabolic dysfunction, and organ injury, contributing extensively to scientific literature and interdisciplinary collaborations. Her research interests span cardiometabolic injury, diabetes complications, sepsis physiology, osteoporosis biology, redox mechanisms, ferroptosis, nanoformulations, and boron-based dermocosmetic innovations. She is skilled in experimental disease modeling, molecular assays, biomarker analysis, antioxidant therapeutics, nanotechnology-driven drug delivery, and evaluation of natural and synthetic cytoprotective agents. Her contributions include leading and participating in funded scientific projects, developing innovative therapeutic concepts, and offering consultancy for university–industry partnerships focused on bioactive compounds and product development. She has earned recognition through editorial roles in respected journals, active membership in scientific networks, and authorship of book chapters and impactful publications. Dr. Kutlu continues to advance her field with a commitment to rigorous research, innovation, and scientific integrity, and her growing portfolio reflects a career devoted to improving biomedical understanding and fostering solutions that support human health and translational progress.

Profile: Google scholar

Featured Publications

Elif Baris | Pharmacology | Excellence in Research Award

Published on by Cognitive Scientist Awards

Assoc. Prof. Dr. Elif Baris | Pharmacology | Excellence in Research Award

İzmir University of Economics | Turkey

Elif Baris is an Assistant Professor of Medical Pharmacology at Izmir University of Economics, specializing in molecular pharmacology with a strong focus on inflammation, pain physiology, and cholinergic anti-inflammatory mechanisms. She holds a pharmacy degree and a doctoral qualification in medical pharmacology from Dokuz Eylül University, and has developed expertise in cytokine signaling, oxidative stress, neuroimmune modulation, molecular oncology, stem cell immunoregulation, and sepsis models. Her professional experience includes leading and contributing to numerous multidisciplinary research projects supported by national and institutional scientific bodies, alongside collaborations with prominent medical and biotechnology institutions. Her research interests extend to autonomic nervous system pharmacology, neuroimmune interactions, mechanotransduction through TRPV4 channels, and innovative drug repurposing strategies. She possesses strong research skills in qRT-PCR, Western blotting, ELISA, cytokine arrays, flow cytometry, and real-time cell analysis, supported by extensive publications in indexed journals and multiple patents involving varenicline- and choline-based therapeutic applications. She has received recognition through collaborative roles in funded research, chapter authorship in academic publications, and contributions to translational pharmacology. Her professional memberships include national societies in pharmacology and physiology, reflecting her commitment to scientific advancement. With her growing contributions to drug innovation, inflammation therapeutics, and molecular pharmacology, she continues to advance impactful research aimed at improving mechanisms of pain management and immune regulation.

Profile: Google scholar

Featured Publications

Baris, E., Efe, H., Gumustekin, M., Arici, M. A., & Tosun, M. (2021). Varenicline prevents LPS-induced inflammatory response via nicotinic acetylcholine receptors in RAW 264.7 macrophages. Frontiers in Molecular Biosciences, 8, 721533. [15 citations]

Baris, E., Simsek, O., Arici, M. A., & Tosun, M. (2023). Choline and citicoline ameliorate oxidative stress in acute kidney injury in rats. Bratislava Medical Journal / Bratislavské Lekárske Listy, 124(1). [12 citations]

Baris, E., Simsek, O., Efe, H., Oncu, S., Gelal, A., Hamurtekin, E., Tosun, M., … (2021). Effects of CDP-choline and choline on COX pathway in LPS-induced inflammatory response in rats. International Journal of Pharmacology, 17(2), 84–96. [10 citations]

Baris, E., Arici, M. A., & Tosun, M. (2024). Nicotinic acetylcholine receptor-mediated effects of varenicline on LPS-elevated prostaglandin and cyclooxygenase levels in RAW 264.7 macrophages. Frontiers in Molecular Biosciences, 11, 1392689. [4 citations]

 

Chaoyue Huo | Pharmacology & Traditional Medicine | Women Researcher Award

Published on by Cognitive Scientist Awards

Dr. Chaoyue Huo | Pharmacology & Traditional Medicine | Women Researcher Award

Beijing University of Chinese Medicine Third Affiliated Hospital | China

Huo Chaoyue is a dedicated PhD candidate in Gynecology at the Third Affiliated Hospital of Beijing University of Chinese Medicine, specialising in the study of endometriosis and complex gynaecologic disorders such as polycystic ovary syndrome, adenomyosis, and menopause. Her academic journey in Traditional Chinese Medicine has been entirely nurtured at Beijing University of Chinese Medicine, where she advanced through undergraduate and postgraduate studies to her current doctoral research. She possesses extensive clinical experience in gynaecological diagnosis and management, performing and interpreting procedures such as hysteroscopy, colposcopy, and ultrasound for thousands of patients annually. Her research integrates multi-omics approaches, network pharmacology, and mechanistic studies of herbal medicine, particularly focusing on the Hippo/YAP signalling pathway. She has achieved significant recognition as the first author of a Q1-ranked SCI publication in Phytomedicine and is leading ongoing real-world clinical research comparing herbal and conventional therapies for endometriosis. Skilled in molecular biology, animal experimentation, and advanced data analysis using SPSS, R, and Prism, she demonstrates strong interdisciplinary competence. Her innovative contributions have earned multiple provincial awards and national invention patents. Driven by curiosity and compassion, Huo Chaoyue continues to bridge Traditional Chinese Medicine and modern biomedical science to improve women’s reproductive health worldwide.

Profile: scopus

Featured Publications

Qura Ain | Phamagenetics | Women Researcher Award

Published on by Cognitive Scientist Awards

Dr. Qura Ain | Phamagenetics | Women Researcher Award

University College Dublin | Pakistan

Dr. Qura Tul Ain is a passionate pharmacogenetic researcher and medical doctor with a strong dedication to advancing knowledge in rare diseases, human genetics, and advanced health sciences. She completed her MBBS from the Services Institute of Medical Sciences in Lahore, where she gained extensive clinical exposure through rotations in medicine, surgery, intensive care, gynecology, and ophthalmology, and later pursued an MPhil in Pharmacology with a specialization in molecular genetics at Shifa Tameer-e-Millat University, Islamabad. Her academic training provided her with expertise in genomics, bioinformatics, and molecular pharmacology, with her thesis focusing on the pharmacogenetics of low-dose empagliflozin in patients with heart failure. Professionally, she has served as a demonstrator in pharmacology at Shifa College of Medicine, alongside clinical roles as a medical officer and house physician in both medicine and surgical departments. Her research interests include pharmacogenomics, molecular genetics, and personalized medicine, with a particular focus on identifying genetic markers that predict treatment outcomes in cardiovascular diseases. She is skilled in laboratory techniques such as PCR, RFLP, DNA/RNA extraction, and gel electrophoresis, which support her translational research. Her contributions have been recognized through research fellowships and academic opportunities, reflecting her commitment to bridging genetics and clinical therapeutics. With her strong foundation in medicine, research, and teaching, Dr. Qura Tul Ain is well positioned to make impactful contributions to precision medicine and healthcare innovation.

Profile: ORCID

Featured Publications

Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

Published on by Cognitive Scientist Awards

Mr. Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

PhD Scholar at Acharya and BM Reddy College of Pharmacy, Bengaluru, India

Mr. Rohit Pal is a dedicated and emerging researcher in the field of pharmaceutical sciences, particularly focusing on drug discovery and development. Currently pursuing his Ph.D. at Acharya & BM Reddy College of Pharmacy in Bengaluru, he is engaged in innovative research on Pyrimidine derivatives as fourth-generation EGFR inhibitors to combat Non-Small Cell Lung Cancer (NSCLC). With a strong academic background, including an M.Pharmacy in Pharmaceutical Chemistry, Mr. Pal combines his expertise in chemical synthesis with cutting-edge computational techniques like molecular docking and structure-activity relationship (SAR) analysis. His work spans multiple research areas, including anticonvulsant activity, anti-inflammatory research, and the pharmacognostic standardization of endangered species like Passiflora vitifolia. Throughout his career, Mr. Pal has demonstrated a capacity for both in-silico drug design and experimental testing, balancing theoretical approaches with hands-on experimentation. His impressive publication record in respected journals further showcases his capability to contribute to the scientific community. As a promising young researcher, Mr. Pal’s ongoing work not only advances pharmaceutical sciences but also holds potential for meaningful clinical applications in cancer therapy and drug design.

Profile

Orcid

 

Education 🎓

Mr. Rohit Pal’s educational background demonstrates a consistent pursuit of excellence in the field of pharmaceutical sciences. He is currently enrolled in a Ph.D. program at Acharya & BM Reddy College of Pharmacy in Bengaluru, Karnataka, where his research is focused on the development of Pyrimidine derivatives as EGFR inhibitors to target Non-Small Cell Lung Cancer (NSCLC). Prior to his doctoral studies, Mr. Pal completed his M.Pharmacy in Pharmaceutical Chemistry from ISF College of Pharmacy in Moga, Punjab, achieving a notable CGPA of 9.07. His academic journey began with a B. Pharmacy from Dev Bhoomi Institute of Pharmacy and Research, Dehradun, where he gained a robust foundation in pharmaceutical sciences. Additionally, Mr. Pal holds a D. Pharmacy from SGGS College of Pharmacy, Chandigarh, further demonstrating his dedication to the field from the onset of his academic career. His varied educational experiences have shaped his interdisciplinary approach to pharmaceutical research, combining knowledge from chemistry, biology, and computational sciences. This solid academic foundation has propelled Mr. Pal to explore complex drug development challenges, particularly in cancer therapy, with a keen interest in molecular-level drug interactions.

Work Experience 💼

Mr. Rohit Pal’s professional experience reflects a promising trajectory in pharmaceutical research and drug discovery. As a Ph.D. scholar at Acharya & BM Reddy College of Pharmacy, he is deeply involved in researching Pyrimidine derivatives for EGFR inhibition in Non-Small Cell Lung Cancer (NSCLC). His research explores the design, synthesis, and evaluation of novel drug candidates, combining in-vitro testing with computational drug design. Through the use of molecular docking and structure-activity relationship (SAR) analysis, Mr. Pal aims to identify compounds with high therapeutic potential. Beyond his Ph.D. work, Mr. Pal has worked on various other research projects, including 1,2,4-triazine derivatives for anticonvulsant activity and the anti-inflammatory properties of Passiflora vitifolia, an endangered plant species. His work spans both synthetic chemistry and biological testing, allowing him to gain expertise in pharmacological assays and computational modeling. Mr. Pal’s professional experience also includes using sophisticated instruments such as HPLC, UV spectrophotometers, and Microwave Synthesizers, which complement his experimental work and ensure the reliability of his results. These experiences have positioned him well for future leadership roles in pharmaceutical research and drug developmen

Awards and Honors

Although still in the early stages of his academic career, Mr. Rohit Pal has already garnered significant recognition for his research efforts. His academic excellence is reflected in his M.Pharmacy CGPA of 9.07, placing him among the top students in his cohort. Mr. Pal’s research has been published in reputable journals such as the Journal of Biomolecular Structure and Dynamics and Chemical Physics Impact, demonstrating the impact and quality of his work. These publications are indicative of his ability to produce research that contributes to the scientific community. Despite being early in his career, his involvement in cutting-edge research on Pyrimidine derivatives and EGFR inhibitors has already gained attention within the academic and pharmaceutical fields. His dedication to molecular docking, drug design, and pharmacognostic studies positions him for further recognition. As Mr. Pal continues to contribute to innovative drug development solutions, he is likely to receive more prestigious awards and honors, reflecting the growing importance of his work in cancer research and pharmaceutical chemistry.

Research Interests

Mr. Rohit Pal’s research interests are centered around the intersection of pharmaceutical chemistry and drug discovery. His primary focus is on developing Pyrimidine derivatives as fourth-generation EGFR inhibitors aimed at Non-Small Cell Lung Cancer (NSCLC), a serious health concern with limited therapeutic options. By targeting the epidermal growth factor receptor (EGFR), his work could offer more effective treatment alternatives for cancer patients. In addition to cancer research, Mr. Pal has explored 1,2,4-triazine derivatives for evaluating anticonvulsant activity, contributing to neurological disorder treatments. He is also interested in anti-inflammatory research, with a particular focus on Passiflora vitifolia, an endangered plant species, aiming to standardize its pharmacognostic properties. His multidisciplinary approach extends to the application of computational drug design, where he utilizes molecular docking and molecular dynamics simulations to predict drug-receptor interactions. Mr. Pal is committed to advancing drug development by combining experimental chemistry with in-silico methodologies, offering innovative solutions for complex healthcare challenges. His work on drug repurposing, targeted therapies, and sustainable drug sourcing reflects his holistic approach to addressing both scientific and global health concerns.

Research Skills

Mr. Rohit Pal possesses a wide range of research skills essential for successful pharmaceutical research. His proficiency in chemical synthesis includes techniques such as recrystallization, sublimation, and flash chromatography, which he applies to purify and isolate new compounds for testing. In addition to these laboratory techniques, Mr. Pal is highly skilled in analytical methods, including HPLC and UV spectrophotometry, to assess the purity and chemical composition of compounds. He is also adept at utilizing computational tools for drug design, particularly AutoDock, Biovia Drug Discovery Studio, and Pymol, to perform molecular docking and molecular dynamics simulations. These tools allow him to predict the interactions between drug candidates and their targets, enhancing the efficiency of drug development. Furthermore, Mr. Pal has experience in in-vitro biological testing, including assays for anticonvulsant, anti-inflammatory, and antioxidant activities, ensuring the biological relevance of his synthesized compounds. His ability to combine experimental techniques with computational modeling equips him to approach drug discovery from both theoretical and practical angles, ensuring well-rounded and impactful research outcomes.

📚 Publications

  • Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl)pyrimidin-2-amine/thiol/hydroxy derivatives as EGFRWT and EGFRT790M inhibitors targeting NSCLC: In-vitro and in-silico exploration
    • Journal: Journal of Molecular Structure
    • DOI: 10.1016/j.molstruc.2024.141227
    • Date: April 2025
    • Contributors: Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Ghanshyam Teli; Viney Chawla; Pooja A. Chawla
  • Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.117034
    • Date: January 2025
    • Contributors: Ebna Azizal Omar; Rajesh R.; Pronoy Kanti Das; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Lalmohan Maji
  • Benzothiazole a privileged scaffold for cutting-edge anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.116831
    • Date: December 2024
    • Contributors: Aayishamma I; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Abhishek Ghara; Nimmagadda Venkata Satya Sai Aishwarya; Kumaraswamy B; Ketan R. Hosamani; Manjushree B V; Haripriya E
  • An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
    • Journal: Journal of Biomolecular Structure and Dynamics
    • DOI: 10.1080/07391102.2023.2252082
    • Date: December 11, 2024
    • Contributors: Rohit Pal; Ghanshyam Teli; Sindhuja Sengupta; Lalmohan Maji; Gurubasavaraja Swamy Purawarga Matada
  • Exploring the anticancer potential of triazine derivatives: An outlook of designing strategies, docking studies, and structure-activity relationships (SAR)
    • Journal: ChemistrySelect
    • DOI: 10.1002/slct.202402766
    • Date: November 2024
    • Contributors: B. V. Manjushree; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Md. Ashadul Sk; M. P. Viji; Nimmagadda Venkata Satya Sai Aishwarya; Pronoy Kanti Das; I. Aayishamma; S. Mounika
  • Pyrazole, pyrazoline, and fused pyrazole derivatives: New horizons in EGFR-targeted anticancer agents
    • Journal: Chemistry & Biodiversity
    • DOI: 10.1002/cbdv.202400880
    • Date: November 2024
    • Contributors: Ketan R Hosamani; Hemalatha K; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Kumaraswamy B; Aayishamma I; Nimmagadda Venkata Satya Sai Aishwarya

Conclusion 

Mr. Rohit Pal is an exceptionally talented and promising researcher in the field of pharmaceutical sciences. His research, focused on Pyrimidine derivatives as EGFR inhibitors for Non-Small Cell Lung Cancer (NSCLC), is not only innovative but holds significant promise for advancing cancer treatment. His combination of chemical synthesis, computational drug design, and biological testing reflects his multidisciplinary approach to pharmaceutical research. Mr. Pal’s commitment to anti-inflammatory, anticonvulsant, and pharmacognostic standardization further demonstrates his versatility as a researcher. While still in the early stages of his career, his publication record and expertise in molecular docking and drug design suggest that he is well on his way to becoming a leader in pharmaceutical research. His ongoing work could contribute to groundbreaking advancements in cancer therapy, neurological disorder treatments, and sustainable drug sourcing. With his strong educational background, solid professional experience, and growing body of work, Mr. Rohit Pal is undoubtedly a candidate with the potential to make meaningful contributions to drug development and global health. His future in research looks bright, and he is well-positioned for recognition in upcoming awards such as the Young Scientist Award.